



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2294515 C 2007/08/28

(11)(21) **2 294 515**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1998/06/26
(87) Date publication PCT/PCT Publication Date: 1999/01/07
(45) Date de délivrance/Issue Date: 2007/08/28
(85) Entrée phase nationale/National Entry: 1999/12/22
(86) N° demande PCT/PCT Application No.: US 1998/013459
(87) N° publication PCT/PCT Publication No.: 1999/000383
(30) Priorité/Priority: 1997/06/27 (US60/051,170)

(51) Cl.Int./Int.Cl. *C07D 409/06* (2006.01),
A61K 31/4178 (2006.01), *A61K 31/44* (2006.01),
A61K 31/54 (2006.01), *A61K 31/635* (2006.01),
A61K 38/55 (2006.01)
(72) Inventeurs/Inventors:
DUDDU, SARMA, US;
PALEPU, NAGESWARA R., US;
VENKATESH, GOPADI M., US
(73) Propriétaire/Owner:
SMITHKLINE BEECHAM CORPORATION, US
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : EPROSARTANE MONOHYDRATE
(54) Title: EPROSARTAN MONOHYDRATE

(57) **Abrégé/Abstract:**

This invention relates to (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 409/06, A61K 31/415	A1	(11) International Publication Number: WO 99/00383 (43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US98/13459 (22) International Filing Date: 26 June 1998 (26.06.98) (30) Priority Data: 60/051,170 27 June 1997 (27.06.97) US (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DUDDU, Sarma [IN/US]; 170 Dawn Drive, Lansdale, PA 19446 (US). PALEPU, Nageswara, R. [US/US]; 2048 Hollis Road, Lansdale, PA 19446 (US). VENKATESH, Gopadi, M. [US/US]; 75 Guilford Circle, Phoenixville, PA 19406 (US). (74) Agents: McCARTHY, Mary, E. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: EPROSARTAN MONOHYDRATE (57) Abstract This invention relates to (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.		

Eprosartan MonohydrateField of the Invention

This invention relates to a pharmaceutically active compound, compositions
5 containing the compound and methods of using the compound in the treatment of
certain disease states in mammals, in particular man. More specifically, the present
invention relates to (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-
yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate,
compositions containing this compound, and methods of using (E)- α -[2-n-butyl-1-
10 [(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid
monomethanesulfonate monohydrate to block angiotensin II (AII) receptors and to
treat hypertension, congestive heart failure and renal failure.

Background of the Invention

15 The compound (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-
5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate is known by the
name "eprosartan" and is the subject of U.S. Patent No. 5,185,351 (the '351 patent),
issued February 9, 1993. This patent discloses in Example 41 a process for making
the anhydrous form of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-
20 5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate. Additionally,
the '351 patent discloses conventional techniques for formulating (E)- α -[2-n-butyl-
1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic
acid monomethanesulfonate and Examples 108-111 specifically detail the
preparation of certain formulations. This compound is claimed to have utility in
25 blocking angiotensin II receptors and to be useful in the treatment of hypertension,
congestive heart failure and renal failure.

It has been found that the monohydrate of (E)- α -[2-n-butyl-1-[(4-
carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid
monomethanesulfonate is formed during the vacuum drying of the dihydrated form
30 of this compound or when the anhydrate of (E)- α -[2-n-butyl-1-[(4-carboxy-
phenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid
monomethanesulfonate is granulated with water, stored at 50°C overnight and
vacuum dried overnight at ambient temperature.

35

Summary of the Invention

The present invention provides a novel monohydrate of (E)- α -[2-n-butyl-1-
[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid

monomethanesulfonate, in particular, in pharmaceutical compositions for the treatment of diseases in which blockade of angiotensin II receptors is indicated, for example, in the treatment of hypertension, congestive heart failure and renal failure.

5

10

The anhydrous form of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate exhibits a single thermal event, a melting endotherm at about 250°C associated with a weight loss, suggesting that melting is followed by decomposition of the drug substance.

15

No significant weight loss prior to melting is observed in its TGA, suggesting that this compound does not contain significant quantities of surface adsorbed water and/or residual solvents. The powder X-ray diffraction pattern exhibits characteristic diffraction lines corresponding to 2 θ values of 7, 14, 18.9, 22.2 and 29 degrees.

20

The DSC of the dihydrated form of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate exhibits 3 characteristic endothermic

25 peaks at about 71°C, 99°C and 250°C. The exotherm at 124°C corresponds to the recrystallization of eprosartan dihydrate to the anhydrate upon dehydration. A typical TGA for the dihydrate exhibits a two-step moisture loss in the temperature range of 25-125°C. The loss of water associated with the first-step moisture loss begins at 25°C and is essentially complete by 70°C. This weight loss amounts to about 3%, corresponding stoichiometrically to one mole of water per mole of eprosartan anhydrate. The water associated with the second-step moisture loss is lost in the temperature range of 75°-125°C. The dihydrate also exhibits a characteristic powder X-ray diffraction. The XRD exhibits characteristic diffraction lines corresponding to 2 θ values of 8, 10.8, 16.8, 21.9, 26.6 and 30.4 degrees.


35

The DSC of the monohydrate of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate exhibits an endothermic peak at about 98°C and an exothermic peak at about 128°C. A typical TGA for the monohydrate exhibits a one-step moisture loss in the temperature range of 25-120°C.

The monohydrate also exhibits a characteristic powder X-ray diffraction.

Detailed Description of the Invention

(E)- α -[2-n-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate is known to exist in an anhydrous form. This compound has the following structure:



(E)- α -[2-n-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate, eprosartan, is claimed in U.S. Patent No. 5,185,351. Reference should be made to said patent for its full disclosure, including the methods of preparing and using this compound.

Eprosartan is anhydrous, and, by itself, is stable at ambient temperature and humidity, as well as at accelerated conditions (30°C/79%RH or 40°C/75%RH for up to 6 months). This drug substance does not pick up moisture at higher humidities (typically up to 95%RH). However, the anhydrous form of the compound converts to the hydrated form, if it is moistened prior to storage in a closed container at ambient or higher temperatures, or if the dry powder is stored at a relative humidity of 98% or higher at ambient or higher temperatures for 8 days or longer. In the former case where the hydrate is obtained by moistening the drug substance, the hydrated form is not stable, and is generally converted back into the anhydrous form during drying.

In accordance with the present invention, it has been found that a monohydrated form of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate is produced during the vacuum drying of the dihydrated form of this compound or when the
5 anhydrate of (E)- α -[2-n-butyl-1-[(4-carboxy-phenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate is granulated with water, stored at 50°C overnight and vacuum dried overnight at ambient temperature.

According to the instant invention, the dihydrate prepared using different excipients behave differently in terms of ease of conversion of the dihydrate to the
10 monohydrate during vacuum drying. Continued vacuum drying of moist granulations results in partial to complete conversion of the dihydrate initially formed to the monohydrate. For example, the dihydrate formed in granulations containing excipients, such as soluble starch, xanthan gum and gelatin, stored for for up to 24 hrs, was found to convert to the monohydrate form upon vacuum drying.
15 Eprosartan granulated with water, stored at 50°C overnight and vacuum dried overnight at ambient temperature was also found to be a monohydrate. However, there is always a possibility of getting a mixture of a monohydrate, a dihydrate and an anhydrate depending on the length or severity of vacuum drying.

The two tables, below, summarize the powder X-ray diffraction (XRD)
20 pattern and the FTIR [Fourier transform infrared] spectroscopic data of the anhydrate, the monohydrate and the dihydrate of (E)- α -[2-n-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate.

Table 1 : Powder X-Ray Data

X-Ray Peak Position, 2 θ (Relative Intensity)		
Anhydrate	Monohydrate	Dihydrate
7.15 (82)	8.55 (37)	8.45 (36)
	9.40 (20)	9.95 (20)
		10.80 (22)
13.90 (22)	12.60 (13)	12.35 (14)
14.35 (24)	14.35 (16)	14.00 (15)
	15.80 (35)	15.90 (27)
	17.25 (100)	16.80 (93)
18.30 (50)	18.25 (58)	18.10 (27)
18.9 (100)	19.25 (43)	18.45 (36)
20.10 (58)	19.70 (92)	18.70 (40)
20.45 (41)	20.90 (34)	20.05 (59)
21.00 (44)	21.55 (41)	20.75 (68)
	21.75 (68)	21.45 (81)
22.20 (55)	22.15 (60)	21.90 (100)
	22.60 (71)	22.60 (71)
	22.90 (79)	
24.35 (43)	23.45 (84)	24.65 (71)
	26.60 (34)	26.60 (35)
	27.25 (38)	27.45 (16)
	28.70 (35)	29.10 (21)
28.95 (21)		
	31.05 (37)	30.40 (29)
34.20 (8)	35.05 (20)	35.85 (10)

(Note: Characteristic diffraction peaks are highlighted)

Table 2 : FTIR Data

Anhydrate	Monohydrate	Dihydrate
1714	1725	1705
1692	1703	1690
1650	1638	1640
	1613	1614
1539	1534	1538
1505	1504	1511
1429	1419	1438
1384	1379	1384
		1289
1215	1229	1238
1050	1044	1042
851	845	846
712	711	704

(E)- α -[2-n-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate may be co-

5 administered with other pharmaceutically active compounds, for example, in physical combination or by sequential administration. Conveniently, the compound of this invention and the other active compound are formulated in a pharmaceutical composition. Thus, this invention also relates to pharmaceutical compositions comprising (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-

10 yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate, a pharmaceutically acceptable carrier, and a second pharmaceutically active

compound selected from the group consisting of a diuretic, a calcium channel blocker, a β -adrenoceptor blocker, a renin inhibitor, and an angiotensin converting enzyme inhibitor. Examples of compounds which may be included in pharmaceutical compositions in combination with (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate are diuretics, particularly a thiazide diuretic, such as hydrochlorothiazide, or a loop diuretic, such as furosemide, calcium channel blockers, particularly dihydropyridine antagonists, such as nifedipine, β -adrenoceptor blockers, such as propranolol, renin inhibitors, such as enalkinen, and angiotensin converting enzyme inhibitors, such as captopril or enalapril. Preferably, the pharmaceutical composition contains 200-400 mg of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)-methyl]-1H-imidazol-5-yl]methylene-2-thiophene-propionic acid monomethanesulfonate monohydrate in combination with 6.25-25 mg of hydrochlorothiazide.

No unacceptable toxicological effects are expected when (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate is administered in accordance with the present invention.

(E)- α -[2-n-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate is useful for treating diseases in which blockade of the angiotensin II receptor would be beneficial. Preferably, this compound is used alone or in combination with said second pharmaceutically active compounds in the treatment of hypertension, congestive heart failure and renal failure. Additionally, (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate is of value in the treatment of left ventricular hypertrophy regression, diabetic nephropathy, diabetic retinopathy, mascular degeneration, haemorrhagic stroke, primary and secondary prevention of infarction, prevention of atheroma progression and the regression of atheroma, prevention of restinosis after angioplasty or bypass surgery, improving cognitive function, angina, glaucoma, and CNS disorders, such as anxiety.

The following examples are illustrative of the instant invention. These examples are not intended to limit the scope of this invention as defined hereinabove and as claimed hereinbelow.

In Examples 1-3, below, the term "internals" means the ingredients which are granulated with the anhydrous form of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)-

methyl]-1H-imidazol-5-yl)methylene-2-thiophenepropionic acid monomethanesulfonate.

Examples

5

Examples 1-3

Preparation of (E)- α -[2-n-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene-2-thiophenepropionic Acid Monomethanesulfonate Monohydrate

10

TABLE I

	Example 1	Example 2	Example 3
	(%)	(%)	(%)
<u>Internals</u>			
Compound A*	30-50	60-80	50-70
Lactose, hydrous	15-30	7-20	1-5
Cellulose (Avicel ⁺)	2-15	7-20	-
Starch 1551	2-7	-	-
Povidone (PVP)	-	2-8	-
Purified water	**	**	**

* (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene-2-thiophenepropionic acid monomethanesulfonate, anhydrous form

15 ** Composition does not take into account the formation of the dihydrate during granulation.

Table I, above, summarizes the amounts of Compound A and excipients on a weight for weight basis used in Examples 1-3 below.

20

Example 1

A fluid bed granulator, UniGlatt⁺, is charged with the anhydrous form of (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene-2-thiophenepropionic acid monomethanesulfonate and Impalpable Lactose, homogenized with an aqueous suspension of Starch 1551 and granulated by spraying at a desirable flow rate and dry wet mass to an LOD (loss on drying) of 5.5-6.5% determined using a Sartorius⁺ moisture meter tested at 110°C. The monohydrate is formed during the vacuum drying of the dihydrated form of this compound.

Example 2

5 The internals are premixed in the Collette bowl for 1 min at a low chopper setting and granulated for 4 min by adding water (added in parts) at a high chopper setting. The granulate is then milled through an appropriate screen and dried to an LOD of 5.5-6.5%. The monohydrate is formed during the vacuum drying of the dihydrated form of this compound.

Example 3

10 The internals are premixed in a high shear granulator and granulated at a high chopper setting with hydrous lactose added in solution. The monohydrate is formed during the vacuum drying of the dihydrated form of this compound.

Example 4

15 Preparation of (E)- α -[2-n-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic Acid Monomethanesulfonate Dihydrate

Eprosartan anhydrate was suspended in an aqueous solution of 3.0 M methanesulfonic acid. The suspension was continuously stirred and heated to 65-70°C. The filtrate obtained by suction was maintained at 75°C for several minutes
20 to ensure the absence of the anhydrate in solution. The solution was slowly cooled to ambient temperature and clear colorless crystalline drug substance was harvested by filtration and air dried. The monohydrate is formed during the vacuum drying of the dihydrated form of this compound.

25 It is to be understood that the invention is not limited to the embodiments illustrated hereinabove and the right is reserved to the illustrated embodiments and all modifications coming within the scope of the following claims.

What is claimed is:

1. A compound which is (E)- α -[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate
5 monohydrate.
2. A pharmaceutical composition comprising the compound according to claim 1, a pharmaceutically acceptable carrier and a second pharmaceutically active compound selected from the group consisting of a diuretic, a calcium channel
10 blocker, a β -adrenoreceptor blocker, a renin inhibitor, and an angiotensin converting enzyme inhibitor.
- 3.. The pharmaceutical composition according to claim 2 wherein the second pharmaceutically active compound is a diuretic.
15
4. The pharmaceutical composition according to claim 3 wherein the diuretic is hydrochlorothiazide.
5. The pharmaceutical composition according to claim 2 wherein the
20 second pharmaceutically active compound is a loop diuretic.
6. The pharmaceutical composition according to claim 5 wherein the loop diuretic is furosemide.
- 25 7. The pharmaceutical composition according to claim 2 wherein the second pharmaceutically active compound is a calcium channel blocker.
8. The pharmaceutical composition according to claim 7 wherein the calcium channel blocker is nifedipine.
30
9. The pharmaceutical composition according to claim 2 wherein the second pharmaceutically active compound is a β -adrenoreceptor blocker.
10. The pharmaceutical composition according to claim 9 wherein the β -
35 adrenoreceptor blocker is propranolol.

11. The pharmaceutical composition according to claim 2 wherein the second pharmaceutically active compound is an angiotensin converting enzyme inhibitor.

5 12. The pharmaceutical composition according to claim 11 wherein the angiotensin converting enzyme inhibitor is captopril or enalapril.

13. The pharmaceutical composition according to claim 2 wherein the second pharmaceutically active compound is a renin inhibitor.

10

14. The pharmaceutical composition according to claim 13 wherein the renin inhibitor is enalkinen.

15

20

25

30

35

15. Use of a pharmaceutically effective amount of a compound of claim 1 to block angiotensin II receptors.
16. Use of a pharmaceutically effective amount of a compound of claim 1 in the manufacture of a medicament to block angiotensin II receptors.
17. Use of a pharmaceutically effective amount of a compound of claim 1 to treat hypertension.
18. Use of a pharmaceutically effective amount of a compound of claim 1 in the manufacture of a medicament to treat hypertension.
19. Use of a pharmaceutically effective amount of a compound of claim 1 for stepwise use or use in physical combination with a second pharmaceutically active compound selected from the group consisting of a diuretic, a calcium channel blocker, a β -adrenoreceptor blocker, a renin inhibitor and an angiotensin converting enzyme inhibitor to treat hypertension.
20. Use of a pharmaceutically effective amount of a compound of claim 1 to treat congestive heart failure.
21. Use of a pharmaceutically effective amount of a compound of claim 1 in the manufacture of a medicament to treat congestive heart failure.
22. Use of a pharmaceutically effective amount of a compound of claim 1 to treat renal failure.
23. Use of a pharmaceutically effective amount of a compound of claim 1 in the manufacture of a medicament to treat renal failure.